RU98118574A - METHOD OF DESTRUCTION OF UNWANTED TARGET CELLS - Google Patents

METHOD OF DESTRUCTION OF UNWANTED TARGET CELLS

Info

Publication number
RU98118574A
RU98118574A RU98118574/14A RU98118574A RU98118574A RU 98118574 A RU98118574 A RU 98118574A RU 98118574/14 A RU98118574/14 A RU 98118574/14A RU 98118574 A RU98118574 A RU 98118574A RU 98118574 A RU98118574 A RU 98118574A
Authority
RU
Russia
Prior art keywords
immunotoxins
cells
fragments
mos31
antibodies
Prior art date
Application number
RU98118574/14A
Other languages
Russian (ru)
Other versions
RU2182493C2 (en
Inventor
Эйстейн Фодстад
Гуннар Квальхейм
Сири Юэлль
Менг Ю Ванг
Олав Энгебротен
Original Assignee
Фодстад
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO961031A external-priority patent/NO961031D0/en
Application filed by Фодстад filed Critical Фодстад
Publication of RU98118574A publication Critical patent/RU98118574A/en
Application granted granted Critical
Publication of RU2182493C2 publication Critical patent/RU2182493C2/en

Links

Claims (12)

1. Способ уничтожения клеток рака молочной железы или других карциномных клеток, экспрессирующих те же самые антигены-мишени, в клеточной популяции, включающей имеющие ядро клетки, собранные из периферической крови, или CD34+ клетки, выбранные из указанных выше клеток, имеющих ядро, или другие незрелые/ранние клетки-предшественники из крови, содержащей мультипотентные стволовые клетки, отличающийся тем, что клеточную популяцию экспонируют с комбинацией из двух иммунотоксинов, где каждый иммунотоксин состоит из конъюгата антитела и клеточного токсина, фрагментов антител и токсина или рекомбинантно полученных антител, токсинов, иммунотоксинов или их фрагментов, где антитела направлены к эпитопам антигена EGP2, экспрессируемого геном GA733, и к эпитопам антигена, экспрессируемого генами MUC1, MUC2 или MUC3, соответственно, или их комбинации, а токсин представляет собой экзотоксин A Pseudomonas.1. A method of killing breast cancer cells or other carcinoma cells expressing the same target antigens in a cell population comprising nucleated cells collected from peripheral blood, or CD34 + cells selected from the above cells having a nucleus, or other immature / early progenitor cells from blood containing multipotent stem cells, characterized in that the cell population is exposed with a combination of two immunotoxins, where each immunotoxin consists of an antibody conjugate and a cell the toxin, antibody fragments and toxin, or recombinantly produced antibodies, toxins, immunotoxins or fragments thereof, where the antibodies are directed to epitopes of the EGP2 antigen expressed by the GA733 gene and to epitopes of the antigen expressed by the MUC1, MUC2 or MUC3 genes, respectively, or a combination thereof, and the toxin is Pseudomonas exotoxin A. 2. Способ по п.1, отличающийся тем, что применяемые антитела представляют собой МОС31 и антитело, направленное к антигенам, кодируемым генами MUC1, MUC2, MUC3, или их комбинации. 2. The method according to claim 1, characterized in that the antibodies used are MOS31 and an antibody directed to antigens encoded by the MUC1, MUC2, MUC3 genes, or combinations thereof. 3. Способ по пп.1 и 2, отличающийся тем, что применяемые антитела представляют собой МОС31 и ВМ7 или их фрагменты. 3. The method according to claims 1 and 2, characterized in that the antibodies used are MOS31 and BM7 or fragments thereof. 4. Способ по п. 1 или 2, отличающийся тем, что применяемые антитела представляют собой МОС31 и ВМ2 или 12Н12, или их фрагменты. 4. The method according to p. 1 or 2, characterized in that the antibodies used are MOS31 and BM2 or 12H12, or fragments thereof. 5. Способ по п. 1 или 2, отличающийся тем, что применяемые антитела представляют собой МОС31 и 595А6 или их фрагменты. 5. The method according to p. 1 or 2, characterized in that the antibodies used are MOS31 and 595A6 or fragments thereof. 6. Способ по п. 1, отличающийся тем, что специфические иммунотоксины вводят in vivo. 6. The method according to p. 1, characterized in that the specific immunotoxins are administered in vivo. 7. Способ по п.6, отличающийся тем, что иммунотоксины вводят системно, особенно в случае распространения злокачественных клеток в такие ткани, как кость и костный мозг. 7. The method according to claim 6, characterized in that the immunotoxins are administered systemically, especially in the case of the spread of malignant cells into tissues such as bone and bone marrow. 8. Способ по п.6, отличающийся тем, что иммунотоксины вводят непосредственно в опухоль или в плевральную или брюшную полости. 8. The method according to claim 6, characterized in that the immunotoxins are administered directly into the tumor or into the pleural or abdominal cavity. 9. Препарат из двух иммунотоксинов для уничтожения клеток способом по п. 1, отличающийся тем, что он содержит два иммунотоксина, направленных к антигенам, присутствующим на злокачественных клетках. 9. The preparation of two immunotoxins for the destruction of cells by the method according to p. 1, characterized in that it contains two immunotoxins directed to antigens present on malignant cells. 10. Препарат по п.9, отличающийся тем, что антитела выбраны из МОС31 и ВМ7, 595А6, ВМ2, 12Н12 или их комбинации, или их фрагментов, а токсин представляет собой природный или рекомбинантный экзотоксин A Pseudomonas или его фрагменты. 10. The drug according to claim 9, characterized in that the antibodies are selected from MOS31 and BM7, 595A6, BM2, 12H12, or a combination thereof, or fragments thereof, and the toxin is a natural or recombinant Pseudomonas exotoxin A or fragments thereof. 11. Применение препарата из двух иммунотоксинов по п.9 для производства терапевтического средства против рака. 11. The use of a preparation of two immunotoxins according to claim 9 for the manufacture of a therapeutic agent against cancer. 12. Набор для выполнения метода по п.1, характеризующийся тем, что он содержит препарат из двух иммунотоксинов в фармацевтически приемлемом составе. 12. The kit for performing the method according to claim 1, characterized in that it contains a preparation of two immunotoxins in a pharmaceutically acceptable composition.
RU98118574/14A 1996-03-13 1997-03-12 Method for eliminating undesirable target cells RU2182493C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO961031A NO961031D0 (en) 1996-03-13 1996-03-13 Procedure for killing unwanted target cells
NO961031 1996-03-13

Publications (2)

Publication Number Publication Date
RU98118574A true RU98118574A (en) 2000-07-20
RU2182493C2 RU2182493C2 (en) 2002-05-20

Family

ID=19899150

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98118574/14A RU2182493C2 (en) 1996-03-13 1997-03-12 Method for eliminating undesirable target cells

Country Status (18)

Country Link
US (1) US7198787B2 (en)
EP (1) EP0954329B1 (en)
JP (1) JP2000507230A (en)
CN (1) CN1218411A (en)
AT (1) ATE222122T1 (en)
AU (1) AU710184B2 (en)
BR (1) BR9708049A (en)
CA (1) CA2248620A1 (en)
DE (1) DE69714775T2 (en)
HU (1) HUP9901597A3 (en)
IL (1) IL126014A0 (en)
NO (1) NO961031D0 (en)
NZ (1) NZ331763A (en)
PL (1) PL328804A1 (en)
RU (1) RU2182493C2 (en)
SK (1) SK125798A3 (en)
TR (1) TR199801795T2 (en)
WO (1) WO1997033611A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7496291B2 (en) * 2006-03-21 2009-02-24 Hewlett-Packard Development Company, L.P. Method and apparatus for interleaved image captures
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
CA3069081C (en) 2008-09-20 2023-05-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
AU2009305550B2 (en) * 2008-10-17 2014-06-12 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
CN102665748A (en) 2009-05-27 2012-09-12 达娜-法勃肿瘤研究所公司 Inhibition 0f inflammation using antagonists of MUC1
CN102127148B (en) * 2010-01-14 2013-04-03 中国农业科学院北京畜牧兽医研究所 Polypeptide in cluster-of-differentiation part on surface of vascular endothelial cell and use thereof
ES2641877T3 (en) * 2011-05-06 2017-11-14 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mesothelin-directed recombinant immunotoxin
CN107748256B (en) * 2017-10-11 2020-04-14 厦门骁科码生物科技有限公司 Liquid biopsy detection method for circulating tumor cells

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219411A (en) 1978-09-18 1980-08-26 California Institute Of Technology Cell sorting apparatus
US4230685A (en) 1979-02-28 1980-10-28 Northwestern University Method of magnetic separation of cells and the like, and microspheres for use therein
US4510244A (en) 1980-04-17 1985-04-09 The Board Of Trustees Of The Leland Stanford Jr. University Cell labeling with antigen-coupled microspheres
AU563827B2 (en) 1982-07-01 1987-07-23 Millipore Corp. Filtration apparatus
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4704255A (en) 1983-07-15 1987-11-03 Pandex Laboratories, Inc. Assay cartridge
US4920061A (en) 1984-03-02 1990-04-24 The University Of Texas System Biological magnetic colloids
US4752569A (en) 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US5019497A (en) 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
US4710472A (en) 1985-09-25 1987-12-01 The United States Of America As Represented By The Secretary Of The Navy Magnetic separation device
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
EP0241042A3 (en) 1986-04-11 1988-05-04 Hitachi, Ltd. A method for cell analysis
US4895706A (en) 1986-10-28 1990-01-23 Costar Corporation Multi-well filter strip and composite assemblies
US4857452A (en) 1986-12-04 1989-08-15 E. I. Du Pont De Nemours And Company Assay for carcinoma of breast, colon and ovary
US5194300A (en) 1987-07-15 1993-03-16 Cheung Sau W Methods of making fluorescent microspheres
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5256532A (en) 1988-05-02 1993-10-26 Zynaxis Technologies, Inc. Methods, reagents and test kits for determination of subpopulations of biological entities
FR2638848B1 (en) 1988-11-04 1993-01-22 Chemunex Sa METHOD OF DETECTION AND / OR DETERMINATION IN A LIQUID OR SEMI-LIQUID MEDIUM OF AT LEAST ONE ORGANIC, BIOLOGICAL OR MEDICINAL SUBSTANCE, BY AN AGGLUTINATION METHOD
DE68919715T2 (en) 1988-12-28 1995-04-06 Stefan Miltenyi METHOD AND MATERIALS FOR HIGHLY GRADUATED MAGNETIC SPLITTING OF BIOLOGICAL MATERIALS.
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
GB8905001D0 (en) 1989-03-04 1989-04-19 Univ Leicester Screening for natural products of microbial metabolism
WO1990010692A1 (en) 1989-03-15 1990-09-20 University Of Florida Monoclonal antibody for use in detection and treatment of childhood leukemia
US5081030A (en) 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
DE3919923A1 (en) 1989-06-19 1990-12-20 Behringwerke Ag MAGNETIC PROTEIN CONJUGATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3919873A1 (en) 1989-06-19 1990-12-20 Behringwerke Ag MAGNETIC PROTEIN CONJUGATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
GB8916859D0 (en) 1989-07-24 1989-09-06 Dynal As Hapten linking
JPH05503632A (en) * 1989-12-14 1993-06-17 スローン　―　ケターリング・インスティチュート・フォー・キャンサー・リサーチ Therapeutic use of the hypervariable region of monoclonal antibody M195 and its construction
GB8929297D0 (en) 1989-12-29 1990-02-28 Dynal As Method of separation
GB9007966D0 (en) 1990-04-09 1990-06-06 Dynal As Antigen/anti-antigen cleavage
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5340719A (en) 1990-11-23 1994-08-23 Corporation Coulter Method and apparatus for optically screening microscopic cells
JPH05107249A (en) 1991-02-04 1993-04-27 Toyobo Co Ltd High-sensitivity detection method of ligand/receptor reaction
US5491068A (en) 1991-02-14 1996-02-13 Vicam, L.P. Assay method for detecting the presence of bacteria
AU2115092A (en) 1991-10-08 1993-04-22 Eastman Kodak Company Method, test device and kit for assay of specific binding ligand using controlled flow through filtration membrane
US5290707A (en) 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5256542A (en) 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
CA2131090A1 (en) 1992-03-20 1993-09-21 Peter Leonard Grant Method and apparatus for the analysis of biological material
US5422277A (en) 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1994002016A1 (en) * 1992-07-28 1994-02-03 Steven Kessler Methods for positive immunoselection of stem cells
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
ES2123063T3 (en) 1992-09-14 1999-01-01 Stanford Res Inst Int UPGRADED CONVERTER MARKERS FOR BIOLOGICAL TESTS AND OTHERS THROUGH LASER EXCITATION TECHNIQUES.
FR2700010B1 (en) 1992-12-24 1995-03-17 Rocher Yves Biolog Vegetale Method and device for testing the reactivity of cells with regard to products.
US5374531A (en) 1993-03-22 1994-12-20 Zynaxis, Inc. Immunoassay for determination of cells
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
NO180658C (en) 1994-03-10 1997-05-21 Oeystein Fodstad Method and Device for Detecting Specific Target Cells in Specialized or Mixed Cell Populations and Solutions Containing Mixed Cell Populations
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry

Similar Documents

Publication Publication Date Title
Blacher et al. Squamous cell carcinoma of renal pelvis
Frost et al. A phase I/IB trial of murine monoclonal anti‐GD2 antibody 14. G2a plus interleukin‐2 in children with refractory neuroblastoma: a report of the Children's Cancer Group
RU98118574A (en) METHOD OF DESTRUCTION OF UNWANTED TARGET CELLS
BRPI0416028A (en) compound, compound and antibody-drug conjugates, pharmaceutical compositions, uses of the conjugates, methods for treating cancer, an autoimmune disease, an infectious disease and a patient, method for inhibiting proliferation or killing the cells of tumor or cancer cells, tumor cell growth inhibition method, analysis to detect cancer cells and article of manufacture
RU2005130173A (en) USE OF LECTINS FOR ACTIVATION OF OLIGOMERIZATION OF Glycoproteins and Antigenic Molecules
Suster et al. Dendritic fibromyxolipoma: clinicopathologic study of a distinctive benign soft tissue lesion that may be mistaken for a sarcoma
RU2113224C1 (en) Polypeptide substance, method of its preparing and pharmaceutical composition showing antitumor and analgetic activity
Jhavar et al. Primary extranodal mucosa associated lymphoid tissue (MALT) lymphoma of the prostate
Dayan et al. Ancient neurilemmoma (schwannoma) of the oral cavity
Holden et al. The detection of endothelial cell antigens in cutaneous tissue using methacarn and periodate lysine paraformaldehyde fixation
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
HUP9901597A2 (en) Method of killing target cells in harvested cell populations with one or more immuno-toxins
RU93042874A (en) POLYPEPTIDE NATURE COMPOUNDS, METHOD FOR THEIR PRODUCTION, A COMPOSITION ON THEIR BASIS, THEIR APPLICATION IN ANTI-CANCER THERAPY
EP0112093A2 (en) Novel monoclonal hybridoma and corresponding antibody
EP1696028A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
Vogel et al. Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy
Sundström et al. Radio-immunolocalization in nude mice using anticytokeratin monoclonal antibodies
Mirra et al. Myxoid angioblastomatosis of bones: A case report of a rare, multifocal entity with light, ultramicroscopic, and immunopathologic correlation
SE0000597D0 (en) Novel antibody
Terry et al. Cystic adventitial disease
Sasadaira et al. Immunohistochemical identification of actomyosin‐containing (myoepithelial) cells in non‐neoplastic and neoplastic tissues
Lundbeck et al. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin: initial treatment results and the long-term course
Shanon Total thyroidectomy: Rationale, technique, and morbidity
Holz et al. Monoclonal antibodies in cancer therapy: new perspectives after the colorectal carcinoma trial
EP0681480B1 (en) Recognin vaccines